TickerFacts.

Jasper Therapeutics, Inc. (JSPR): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$1.06M
Year ended 2025-12-31
$561.0K
Trailing 12 months to 2026-06-30
+2.7%
3-year compound annual growth
$1.37M2021-12-31: $377.0K2022-12-31: $975.0K2023-12-31: $1.11M2024-12-31: $1.37M2025-12-31: $1.06M$1.06M
2021-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$1.06M-23.1%2026-03-30, From 2025-01-01
2024-12-31$1.37M+23.9%2026-03-30, From 2024-01-01
2023-12-31$1.11M+13.6%2025-02-28, From 2023-01-01
2022-12-31$975.0K+158.6%2023-03-08, From 2022-01-01
2021-12-31$377.0Kn/a2023-03-08, From 2021-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Jasper Therapeutics, Inc. (JSPR)2025-12-31$1.06M-23.1%
CEL SCI Corp (CVM)2025-09-30$3.89M-2.1%
Champions Oncology, Inc. (CSBR)2026-04-30$1.38M-16.0%
Cognition Therapeutics Inc (CGTX)2025-12-31$36.0K-66.4%
Pluri Inc. (PLUR)2026-06-30$511.0K+61.7%
Sangamo Therapeutics, Inc (SGMOQ)2025-12-31$3.96M-22.4%
Cardiff Oncology, Inc. (CRDF)2025-12-31$364.0K-9.9%
Passage BIO, Inc. (PASG)2025-12-31$728.0K-76.4%
Elutia Inc. (ELUT)2025-12-31$2.79M-19.3%

Compare JSPR, CVM, CSBR, CGTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗